Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | 'Multiple Myeloma Drug market will reach $9.9 billion in 2015' predicts Visiongain reportA new report by visiongain predicts that the world market for multiple myeloma drug sales will reach $9.9bn in 2015.
By: Visiongain James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx’s Kyprolis and Celgene’s Actimid. Both of these have advantages over current drugs, but they’re basically incremental improvements on what we already have – proteasome inhibitors and immunomodulators. “The next real shift for the market will come with the approval of newer mechanisms of action. Promising candidates in the pipeline include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors. However, perhaps the most exciting pipeline drug is elotuzumab by BMS and Abbott, a CS1 glycoprotein- Visiongain’s report shows revenue forecasts to 2022 at overall world market, product and national level. Research, data and analyses cover activities of Celgene, Johnson & Johnson, Novartis, Onyx and other pharmaceutical and biotechnology companies. That study discusses R&D and commercial news and predicts revenues to 2022 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC). World Multiple Myeloma Drug Treatment Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning the visiongain report The World Multiple Myeloma Drug Treatment Market 2012-2022 please visit www.visiongain.com/ For an executive summary please contact: Email: Sara Peerun on sara.peerun@ Tel: +44 (0) 20 7336 6100 Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@ About visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. End
Account Phone Number Disclaimer Report Abuse
|
|